Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and ...
December 05 2016 - 8:00AM
Immune Design, a clinical-stage immunotherapy company focused on
oncology, today announced new data that highlight the broad product
reach potential of both its Specific Antigen and Endogenous
Antigen/Intratumoral immunization approaches.
ZVexMulti offers the potential to create
products that deliver multiple tumor antigens (conserved and/or
neo-antigens) to dendritic cells (DCs) in vivo within the same
product
Immune Design recently presented preclinical
data at SITC 2016 (Poster #195) showing that immunization with
ZVexMulti (multi-genome ZVex) vectors expressing multiple antigens
resulted in consistent induction of polyfunctional CD8 T cells
against all delivered antigens, thereby overcoming the limitation
of antigen competition. Moreover, immune responses were as high as,
or higher than, those obtained by combining individually
manufactured vectors, demonstrating the versatility and potency of
ZVexMulti.
Immune Design scientists have also investigated
the potential for ZVexMulti to deliver multiple MHC Class I and II
putative neo-antigens in the CT.26 colon carcinoma model. Immune
Design believes that ZVexMulti has the potential to deliver a
significantly large number of neo-antigens, thus obviating the need
for a proprietary predictive algorithm tools. These experiments
were performed outside of the previously announced collaboration
with Gritstone Oncology, which the two parties have agreed to
terminate.
“These data collectively illustrate the range
and flexibility of Immune Design’s product discovery platforms to
target both conserved tumor antigens and neo-antigens,” said Jan
ter Meulen, MD, PhD, Chief Scientific Officer at Immune
Design. “These approaches offer the potential to reach a broad
patient population, while addressing some of the current
limitations of other immunization approaches.”
G100 ASH data demonstrate eradication of
lymphomas via synergy with local radiation
At the 58th American Society of Hematology (ASH)
Annual Meeting in San Diego, California, on Monday, December 5 at
6pm Pacific, Immune Design is presenting data (Abstract #4166,
Session: 625, “Intratumoral G100 Rescues Radiation-Induced T Cell
Depletion and Has Synergistic Anti-Tumor Effect with Local
Irradiation in A20 Lymphoma”) showing the synergistic effects of
the G100 product candidate in combination with local radiation
therapy in eradicating lymphomas in preclinical models. These data
further support Immune Design’s ongoing randomized Phase 2 study in
patients with follicular non-Hodgkin’s lymphoma (NHL).
The research, authored by Ramesh Rengan, Eric
Ford and Jeffery L. Schwartz of the University of Washington
Department of Radiation Oncology, and Hailing Lu, Jessica Hewitt,
Frank Hsu and Jan ter Meulen of Immune Design, evaluated the immune
response and therapeutic effects of intratumoral administration of
G100 alone, local radiation alone and G100 and local radiation
given in concomitant therapy in a preclinical model of lymphoma.
Results of combination therapy demonstrated:
- Synergistic antitumor effects in both injected as well as
uninjected tumors (abscopal effects)
- Synergistic induction of pro-inflammatory cytokine and
chemokine environment, as well as induction of genes governing
antigen processing and presentation
- Increased infiltration of T cells, including both CD4 and CD8 T
cells, in treated tumors
- In contrast, tumors that received only radiation but no G100
had significantly decreased levels of T lymphocytes as compared to
untreated tumors
"These findings highlight the potential
beneficial effect that immunotherapy with G100 could provide when
given with radiation by modulating the tumor microenvironment to
generate a systemic, durable T-cell anti-tumor response," said
Ramesh Rengan, M.D., Associate Professor, University of Washington
Department of Radiation Oncology. "As shown in this model, G100 may
hold potential as a treatment for lymphoma patients."
About ZVex and ZVexMulti
ZVex is Immune Design's discovery platform,
initially designed to deliver a single RNA tumor antigen
selectively directly to the patient’s DCs to generate tumor
antigen-specific polyclonal cytotoxic T cells (CTLs). ZVex is
an engineered recombinant viral vector that selectively targets DCs
in vivo to deliver any RNA gene of interest. Further development of
this platform has yielded ZVexMulti, enabling Immune Design to
deliver multiple RNA tumor antigens within the same product
candidate.
About G100
G100 is a product candidate from Immune Design’s
GLAASTM discovery platform. It is a synthetic small molecule
toll-like receptor-4 (TLR-4) agonist, Glucopyranosyl Lipid A (GLA),
formulated in a stable and oil emulsion. G100 is one of the
molecules utilized in Immune Design's intratumoral immune
activation, or Endogenous Antigen, approach. It leverages the
activation of the innate immune system, including DCs, in the tumor
microenvironment to create a robust immune response against the
tumor's preexisting diverse set of antigens. A growing set of
clinical and preclinical data have demonstrated the ability of G100
to activate existing tumor-infiltrating lymphocytes and promote
antigen-presentation and the recruitment of T cells to the tumor to
affect clinical outcome, as well as convert immunosuppressive
M2-type tumor associated macrophages to a pro-inflammatory,
M1-type.
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the primary focus of
Immune Design's ongoing immuno-oncology clinical programs, are
products of its two synergistic discovery platforms, ZVex® and
GLAASTM, the fundamental technologies of which were licensed from
the California Institute of Technology and the Infectious Disease
Research Institute (IDRI), respectively. Immune Design has
offices in Seattle and South San Francisco. For more information,
visit www.immunedesign.com.
Forward Looking Statement:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend", “potential” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on Immune Design's expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
timing, progress, scope and outcome of preclinical studies and
clinical trials, and the clinical application of Immune
Design's product candidates and technology platforms. Many
factors may cause differences between current expectations and
actual results including unexpected safety or efficacy data
observed during preclinical or clinical studies, changes in
expected or existing competition, changes in the regulatory
environment and unexpected litigation or other disputes. Success in
preclinical testing and early clinical trials does not ensure that
later clinical trials will be successful. Other factors that may
cause Immune Design's actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Immune Design's filings
with the U.S. Securities and Exchange Commission, including
the "Risk Factors" sections contained therein. Except as required
by law, Immune Design assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contact for Immune Design:
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206.769.9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024